Dieter Scherer, PhD; Eva Alvarez-Gonzalez, PhD; and Anthony Pettigrew, MSc; examine a proprietary non-protic, aqueous-free ocular delivery system with the potential to provide an alternative approach in particular for poorly soluble drugs.
Kate Farmer, PhD, MBA; Kate Farrell, MEng; Andy Pidgeon; and Anna Rickard, PhD; provide some insight into the reasons behind the low levels of compliance and focus not only on the patient, but consider what the healthcare industry could be doing to tackle the problems.
Jyothi Thundimadathil, PhD, indicates that even though shorter in vivo half-life of peptides is a concern, recent advances in drug delivery systems and peptide modification are expected to override those difficulties.
FORMULATION DEVELOPMENT – KinetiSol: A New Processing Paradigm for Amorphous Solid Dispersion Systems
Dave A. Miller, PhD; James C. DiNunzio, PhD; Justin R. Hughey, PhD; Robert O. Williams III, PhD; and James W. McGinity, PhD; review how a novel fusion-based process for the production of amorphous solid dispersion systems has recently been adapted to pharmaceutical processing and is providing novel solutions for difficult-to-process compounds.
DRUG DELIVERY – Recent Advancements in Drug Delivery: Novel Formulations & Technologies Offer Improved Treatment Options
Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, highlights a few recent innovative approaches to drug delivery with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.
Gerallt Williams, PhD, takes a look at the market forces driving DPI innovation and focuses on a novel solution that has simplicity at the heart of its design, and which hopes to address the growing pressure to reduce healthcare costs, as well as the needs of new markets, arising from emerging economies in South America, India, and China.
PACKAGING – The Impact of Packaging at the Clinical Interface of Vaccine, Healthcare Worker & Patient
Brian Lynch, MBA; and Philip Song, MSc; indicate further adoption of vaccines packaged in PFS is expected to continue, for both new and currently marketed vaccines, particularly as clinicians and vaccine enterprise stakeholders look more closely at the implication of packaging at the user interface and understand the benefits PFS offer in terms of greater efficiency and advancing best care.
Johannes BartholomÃ¤us, PhD; Judy Ashworth, MD; Hans-Jürgen Stahlberg, MD; Eric Galia, PhD; and Kai Strothmann, PhD; examine an innovative drug delivery platform that can significantly raise the hurdle for misuse or abuse of tablets by routes of administration that require the product to first be crushed.
Dinesh Haswani, PhD; John Nagel, MBA; Derek Moe, PhD; and Ehab Hamed, PhD; say formulations developed using OraGuard technology provide overlapping resistance against various tampering methods, such as crushing and ingestion, chewing, small-volume extract
DRUG DEVICES – The Rise of the Bolus Injector – A New Device Class Enabling Long-Duration Subcutaneous Administration of Large-Dose Volume Biologics
Alan Shortall reviews Unilife’s bolus injectors for large-dose volume injectable therapies, and how Unilife is already working with a number of companies to customize each device to address the specific needs of a series of pipeline and approved molecules.
EXCLUSIVE ONLINE CONTENT
Wearable Drug Delivery Provider Sorrel Medical Partners With Leading Global Pharmaceutical Manufacturer
Sorrel Medical recently announced it has entered into a strategic partnership with one of the world’s leading pharmaceutical companies to advance the development and introduction of next-generation wearable drug delivery solutions….
Welcome to Frontage Laboratories 2020 Podcast Series. Listen to our full suite of podcasts of engaging topics from our top scientific experts.
Croda International Plc recently announced it has agreed to acquire Avanti Polar Lipids, Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for next-generation pharmaceuticals…..
Join us as we are hosting an RNA Symposium bringing together leading experts in RNA medicine, delivery, technology development, and solutions for manufacturing to present and discuss…
Lonza Establishes Center of Excellence for Integrated Dry Powder Inhaler Product Development Services
Lonza Pharma & Biotech recently announced the establishment of a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its Bend, OR, site…..